XERS - Xeris Pharmaceuticals GAAP EPS of -$0.10 beats by $0.06 revenue of $32.54M beats by $1.5M
2023-03-08 06:25:58 ET
- Xeris Pharmaceuticals press release ( NASDAQ: XERS ): Q4 GAAP EPS of -$0.10 beats by $0.06 .
- Revenue of $32.54M (+52.3% Y/Y) beats by $1.5M .
- Cash, cash equivalents, and short-term investments at December 31, 2022 was $122.0 million compared to $102.4 million at December 31, 2021. Total shares outstanding at February 28, 2023 was 137,288,602.
-
2023 Financial Guidance
Full-year 2023 financial guidance consists of the following:
- Combined total revenue for Gvoke, Keveyis, Recorlev, and Other 1 Revenue of $135 million to $165 million vs consensus of $152.31M
- Cash utilization from operating activities of $57 million to $77 million
- Year-end cash, cash equivalents, and short-term investments of $45 million to $65 million
- Cash flow breakeven in the fourth quarter
For further details see:
Xeris Pharmaceuticals GAAP EPS of -$0.10 beats by $0.06, revenue of $32.54M beats by $1.5M